Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc.

Biotechnology Healthcare Seattle, WA, United States NAUT (NCM)

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprising instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent probe binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers reagent kits, which include sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Other Biotechnology Companies

View All →

Frequently Asked Questions

Has Nautilus Biotechnology, Inc. had layoffs?
No layoff events have been recorded for Nautilus Biotechnology, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Nautilus Biotechnology, Inc. have?
Nautilus Biotechnology, Inc. has approximately 124 employees.
What industry is Nautilus Biotechnology, Inc. in?
Nautilus Biotechnology, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Nautilus Biotechnology, Inc. a publicly traded company?
Yes, Nautilus Biotechnology, Inc. is publicly traded under the ticker symbol NAUT on the NCM. The company has a market capitalization of approximately $0.25 billion.
Where is Nautilus Biotechnology, Inc. headquartered?
Nautilus Biotechnology, Inc. is headquartered in Seattle, WA, United States at 2701 Eastlake Avenue East, Seattle, WA 98102, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.